Investigational drug · Phase 2
DJI136
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Extensive-stage Small Cell Lung Cancer (ES-SCLC).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "DJI136"
First trial start
2026
Jun 16, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DJI136", any sponsor or status.
Conditions studied
As listed on its trial records.
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "DJI136" as an intervention, largest first.
Novartis PharmaceuticalsNovartis (NVS)
NCT07564401 · 80 participants (planned) · Start Jun 16, 2026 · Primary completion Mar 3, 2031
Drug: DJI136 · For: Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sites: Lexington, Kentucky; Houston, Texas; Seattle, Washington · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.